Annex 1: Measuring progress towards targets
Annex 2: Modelling the impact of the 90-(90)-90 strategy
Annex 3: Investment packages by country setting
Annex 4: Country strategies
Annex 5: Strategic frameworks for research and development for new tools
Annex 6 : Estimating the cost of the 90-(90)-...90 strategy
Accessed November 2017
more
Overcoming HIV-related stigma and discrimination in health- care settings and beyond
UNAIDS 2017 | REFERENCE
This technical package represents a select group of strategies based on the best available evidence to help communities and states sharpen their focus on prevention activities with the greatest potential to prevent suicide
Guidelines
June 2017
HIV strategic information for impact
Global HIV Strategic Information Working Group
For Populations At Risk For HIV
Global HIV Strategic Information Working Group
Establishing trauma referral pathways to provide urgent life-saving assistance for displaced populations and civilians remaining in Ar-Raqqa.
In July 2017, a WHO team comprising an external trauma care specialist and two WHO staff members visited the governorates of Ar-Raqqa and neighbouring Al-Ha...sakeh to assess the situation
more
The International Journal of Tuberculosis and Lung Disease 21(5) DOI: 10.5588/ijtld.16.0518
National Tuberculosis and Leprosy Conrol Programme
UGANDA NATIONAL TUBERCULOSIS AND LEPROSY CONTROL PROGRAMME
Expert opinion of the European Tuberculosis Laboratory Initiative core group members for the WHO European Region.
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more